Form 4: PTC Therapeutics CEO Matthew Klein Reports Stock Sale to Cover Tax Obligations
SEC Form 4 Filing
CEO Matthew Klein of PTC Therapeutics reports the sale of 8,279 shares of common stock to cover tax obligations related to the vesting of restricted stock units (RSUs).
Summary
- On December 31, 2024, Matthew B. Klein, CEO of PTC Therapeutics, sold 8,279 shares of common stock.
- The sale was executed at a price of $45.16 per share.
- This transaction was to cover tax withholding obligations related to the vesting of 18,750 RSUs from a grant of 75,000 RSUs on December 28, 2023.
- Following the transaction, Klein directly owns 217,528 shares of PTC Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (stock sale for tax obligations) and doesn't indicate any significant positive or negative sentiment.
Industry Context
This is a routine transaction related to executive compensation and tax obligations. It is common for executives to sell shares to cover taxes when RSUs vest.
Key Dates
| Date | Description |
|---|---|
| 12/28/2023 | Date of grant of 75,000 RSUs |
| 12/31/2024 | Date of stock sale to cover tax obligations |
| 01/03/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.